Pyxis Oncology, Inc.

Developing next-gen ADC and Immuno-Oncology therapeutics for difficult-to-treat cancers.

PYXS | NDAQ

Overview

Corporate Details

ISIN(s):: US7473241013
LEI:
Country:: United States of America
Address:: 321 HARRISON AVENUE, 2118 BOSTON
Website:: https://pyxisoncology.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing an arsenal of next-generation therapeutics for difficult-to-treat cancers. The company has assembled a differentiated portfolio of clinical assets centered on two key platforms: Antibody-Drug Conjugates (ADCs) and Immuno-Oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for safer and more effective treatments. The company's IO approaches, including monoclonal antibody (mAb) immunotherapies, aim to mobilize the patient's immune system to attack cancer. Pyxis Oncology develops its product candidates as both monotherapies and in combination with other therapies to improve outcomes for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Pyxis Oncology, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pyxis Oncology, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Pyxis Oncology, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ABIONYX Pharma Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.	France	ABNX
Abliva Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.	Sweden	ABLI
Abpro Holdings, Inc. Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.	United States of America	ABP
AB Science Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.	France	AB
ACADIA PHARMACEUTICALS INC Develops and commercializes innovative therapies for CNS disorders and rare diseases.	United States of America	ACAD
Access Bio, Inc. Develops and manufactures rapid diagnostic tests for infectious diseases for global health.	United States of America	950130
ACHIEVE LIFE SCIENCES, INC. Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.	United States of America	ACHV
AC Immune SA Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.	United States of America	ACIU
Aclaris Therapeutics, Inc. A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.	United States of America	ACRS
Actinium Pharmaceuticals, Inc. Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.	United States of America	ATNM